Clinical Trial for Mesothelioma Patients: Bortezomib and Cisplatin Concurrent Therapy

Read about the concurrent therapy criteria for a current clinical trial being conducted to study the effects of Bortezomib and Cisplatin for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This study is being conducted ONLY in the United Kingdom.

Prior Concurrent Therapy:

• See Disease Characteristics

• No prior systemic chemotherapy for mesothelioma

• No other concurrent antineoplastic agents except medications that may have antineoplastic activity but are taken for other reasons (e.g., megestrol acetate, cyclooxygenase-2 inhibitors, or bisphosphonates)

• No other concurrent experimental agents

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney